Hospital.Help

Madrid – Treatment with the antibody lecanemab, which led to visible edema (ARIA E) and bleeding (ARIA H) on magnetic resonance imaging in the first few months, appears to be better tolerated in the long term. According to data presented at a meeting in Madrid, the rate of new ARIA E or H in the open-label follow-up study (OLE) has fallen to “placebo levels”. The effectiveness also seems to persist. Alzheimer’s patients…